Last reviewed · How we verify
Trastuzumab and Pertuzumab — Competitive Intelligence Brief
marketed
Monoclonal antibody
Live · refreshed every 30 min
Target snapshot
Trastuzumab and Pertuzumab (trastuzumab-and-pertuzumab) — Pfizer Inc.. Trastuzumab and pertuzumab target HER2, blocking signal transduction and inhibiting tumor growth in HER2-positive cancers.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trastuzumab and Pertuzumab TARGET | trastuzumab-and-pertuzumab | Pfizer Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trastuzumab and Pertuzumab CI watch — RSS
- Trastuzumab and Pertuzumab CI watch — Atom
- Trastuzumab and Pertuzumab CI watch — JSON
- Trastuzumab and Pertuzumab alone — RSS
Cite this brief
Drug Landscape (2026). Trastuzumab and Pertuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-and-pertuzumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab